NCT06084286View on ClinicalTrials.gov

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells

The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER